3.8 Review

NSAIDs and COVID-19: A New Challenging Area

Journal

PHARMACEUTICAL SCIENCES
Volume 26, Issue -, Pages S49-S51

Publisher

TABRIZ UNIV MEDICAL SCIENCES, FAC PHARMACY
DOI: 10.34172/PS.2020.41

Keywords

NSAIDs; COVID-19; Patients

Ask authors/readers for more resources

Considering the recent controversies regarding the use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in Coronavirus disease 2019 (COVID-19) patients, and due to the limited published data in this field, we reviewed currently available evidence for the use of NSAIDs in viral respiratory tract infections to help make decisions in this area. Currently, there is insufficient evidence to judge the safety and efficacy of NSAIDs in patients with COVID-19. According to the current evidence, acetaminophen is the choice treatment for symptomatic relief. If the patients' symptoms are not controlled by acetaminophen, naproxen may be used as an alternative therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available